Multico Exports Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Multico Exports Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $988.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Multico Exports Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $988.4K Trade | TransData Nexus

Multico Exports Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $988.4K Total Trade · DGFT Verified

Multico Exports Private Limited is an Indian pharmaceutical exporter with a total trade value of $988.4K across 2 products in 2 therapeutic categories. Based on 21 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Clindamycin ($550.0K), Miconazole ($438.4K), .

Multico Exports Private Limited — Export Portfolio & Destination Treemap

Multico Exports Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Multico Exports Private Limited? — Company Overview & Market Position

Multico Exports Private Limited, established on December 21, 1999, is a privately held Indian company specializing in the export of finished pharmaceutical formulations. The company is registered under the Corporate Identification Number (CIN) U51507GJ1999PTC037051 and is classified as a non-government company. Its authorized share capital is ₹500,000, with a paid-up capital of ₹339,000. The registered office is located at Suite 707, Akik Towers, Opposite Rajpath Club, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, India.

Multico Exports operates as a wholesaler and exporter, offering a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated, with its top five products accounting for 100% of its export value. In the fiscal year 2022-2023, Multico Exports reported a total export value of $988,000 USD across 21 shipments, primarily in the therapeutic categories of antibiotics and antifungals.

What Does Multico Exports Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Clindamycin$550.0K 2

Product Portfolio — Top 2 by Export Value

Multico Exports Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Clindamycin	Antibiotics	$550.0K	11	0.6%	7
2	Miconazole	Antifungals	$438.4K	10	2.2%	7

Multico Exports Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $988.4K. The top category is Antibiotics (55.6% of portfolio), followed by Antifungals (44.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Multico Exports Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Multico Exports' manufacturing facilities are not publicly disclosed. The company operates as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to meet international demand. This approach allows Multico Exports to offer a wide range of products without the complexities associated with owning and operating manufacturing plants. The company's registered office is located at Suite 707, Akik Towers, Opposite Rajpath Club, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, India.

3Key Leadership

Multico Exports Private Limited is led by a team of directors who oversee the company's operations and strategic direction. The directors include:

Shobhit Tiwari
Vasishtha Pramodbhai Patel
Rahul Sureshbhai Oze

These individuals bring a wealth of experience to the company, contributing to its growth and success in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Multico Exports Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Multico Exports Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available public records. The company's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. To access these markets, Multico Exports would need to comply with the regulatory requirements set by authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This typically involves obtaining necessary approvals, certifications, and adhering to Good Manufacturing Practice (GMP) standards. The company's ability to meet these regulatory standards would be crucial for its success in these markets.

2Emerging Markets

Multico Exports Private Limited's engagement with emerging markets in Africa, Latin America, and Southeast Asia is not explicitly detailed in the available public records. However, the company's focus on finished pharmaceutical formulations positions it to potentially expand into these regions. Achieving World Health Organization (WHO) prequalification would be a significant step, as it would enable Multico Exports to supply medicines to UN agencies and other international organizations operating in these regions. The prequalification process involves rigorous assessments to ensure that products meet international standards of quality, safety, and efficacy. Successfully obtaining WHO prequalification could enhance the company's credibility and open new avenues for growth in emerging markets.

Multico Exports Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Multico Exports Private Limited's interactions with the U.S. Food and Drug Administration (FDA) are not publicly available. As a wholesaler and exporter of finished pharmaceutical formulations, the company would need to ensure that its products comply with FDA regulations to enter the U.S. market. This compliance typically involves obtaining FDA facility registrations, ensuring that products meet FDA standards, and possibly obtaining approvals for New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generic products. Additionally, the company would need to maintain a clean inspection history, free from FDA Form 483 observations, warning letters, or import alerts, to ensure uninterrupted access to the U.S. market.

2WHO & EU GMP

Multico Exports Private Limited's adherence to international quality standards, such as WHO prequalification and EU Good Manufacturing Practice (GMP) certifications, is not explicitly detailed in the available public records. Obtaining WHO prequalification would enable the company to supply medicines to UN agencies and other international organizations, enhancing its credibility in global markets. Similarly, EU GMP certification would demonstrate compliance with European standards, facilitating access to the European market. The European Directorate for the Quality of Medicines & HealthCare (EDQM) status would further validate the company's commitment to quality. Achieving these certifications would require rigorous assessments and adherence to stringent manufacturing practices.

Multico Exports Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Multico Exports Private Limited operates in a competitive landscape, with numerous pharmaceutical exporters in India and globally. While specific competitors are not identified in the available data, the company's focus on finished pharmaceutical formulations positions it in direct competition with other exporters offering similar products. The company's market share in its top products, such as clindamycin and miconazole, is relatively modest, indicating that it faces competition from both domestic and international players. To enhance its competitive position, Multico Exports may consider strategies such as product diversification, quality enhancement, and exploring new markets.

2Key Differentiators

Multico Exports Private Limited's key differentiators include its focus on finished pharmaceutical formulations, which allows it to offer a comprehensive range of products without the complexities associated with manufacturing. The company's ability to provide a large variety of products within a short time frame and at competitive prices is a significant strength. Additionally, the company's leadership team brings over 20 years of experience in the pharmaceutical field, contributing to its reliability as a supplier.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Multico Exports Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Multico Exports Private Limited has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $988,000 USD across 21 shipments in the fiscal year 2022-2023. The company's ability to provide a large variety of products within a short time frame and at competitive prices indicates reliability and efficiency. However, the concentration of its product portfolio on a few key products suggests potential risks related to market fluctuations and regulatory changes. Potential partners and clients should assess these factors when considering collaboration with the company.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Multico Exports Private Limited

How many pharmaceutical products does Multico Exports Private Limited export from India?

Multico Exports Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Clindamycin ($550.0K), Miconazole ($438.4K). Total export value is $988.4K.

What is Multico Exports Private Limited's total pharmaceutical export value?

Multico Exports Private Limited's total pharmaceutical export value is $988.4K, based on 21 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Multico Exports Private Limited cover?

Multico Exports Private Limited exports across 2 therapeutic categories. The largest are Antibiotics (55.6%, 1 products), Antifungals (44.4%, 1 products).

Get Full Multico Exports Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.